12 Understanding reasons for deviation from lung cancer multidisciplinary team meeting (MDM) recommendations – an audit in a large NHS Foundation Trust
We present data from University Hospitals Birmingham (UHB) NHS Trust (comprising four hospitals). (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Kay Por Yip, Gibril Wardere, Bhavani Adizie, Patricia Glynn Tags: Clinical Networks and Pathways Source Type: research
13 Survey of patients undergoing procedures in a suspected lung cancer and pleural service
Access to diagnostic procedures is instrumental in the faster diagnostic framework and the national optimal lung cancer pathway (NOLCP). We undertook a service evaluation of patient experiences. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Ben Probyn, Gareth Trevelyan, Timothy Howell, Aparna Iyer, Thomas Nicholson, Lindsey Taylor, David Waine, John Corcoran, Cyrus Daneshvar Tags: Clinical Networks and Pathways Source Type: research
14 Widening access and addressing inequalities for patients with lung cancer consenting to systemic anti-cancer therapies (SACT)
Cancer services nationally are under increasing pressure. With new and rapidly emerging therapy lines the consent process for SACT is becoming more complex. Moreover our patient population is more diverse. Research has shown that language services and visual guides can improve patient experience, adherence to treatment and overall health outcomes. We are developing a multi-lingual digital library of animations to support the consent process for SACT with the aim to reduce inequalities in cancer care. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Elizabeth Nally, Annie Reeves, Anna Lerner, Angshu Bhowmik, Pauline Leonard, Oliver Hawkins, David Wald, Adam Januszewski Tags: Clinical Networks and Pathways Source Type: research
15 The Integration and Analysis of Data using Artificial Intelligence to Improve Patient Outcomes with Thoracic Diseases (DART) research programme.
DART is a multi-centre multi-collaborator research programme aiming to improve multiple facets of Lung Cancer Screening (LCS) and provide a very large data set for future research into early lung cancer detection and prognosis. It collects all the clinical metadata, CT scans and PET-CT scans, and pathology from participants both screened and invited to participate in NHS England's Targeted Lung Health Checks (TLHC) screening programme. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Fergus Gleeson Tags: Clinical Networks and Pathways Source Type: research
16 The impact of implanting ctDNA testing on day 0 of the lung cancer pathway in patients with advanced stage disease in Manchester
Circulating tumour DNA (ctDNA) can be detected in peripheral blood of cancer patients and tested for genomic alterations and could support the delivery of the Lung Cancer Optimal Pathway (LCOP). (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Avik Ghoshal, Patrick Goodley, Gaurav Ahuja, Heshani De Silva, Alaa Alsaaty, Charlotte Watson, Richard Booton, Haval Balata, Phil Crosbie, Nicola Sinnott, Jonathan Hiu Nian Chung, Christopher Craig, Matthew Krebs, Anthony Sutcliffe, Matthew Evison Tags: Clinical Networks and Pathways Source Type: research
17 A third treatment pathway: is there a place for a nurse-led Best Supportive Care service for the management of patients diagnosed with lung cancer at an acute NHS Trust?
Cheng et al (2021) identified that patient choice accounted for 56% of BSC decisions in patients who presented as outpatients and 51.3% of those patients managed by BSC were PS 0 –2, highlighting the need for a follow-up service. Following review of this data, the lung cancer CNS team at the UHNM proposed and developed a third treatment arm, running alongside surgery and oncology. This included the implementation of a Best Supportive Care pathway, a standardised electronic assessment tool, and piloting a nurse-led clinic to provide assessment and on-going support. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Laura Fox-Hewitt Tags: Clinical Networks and Pathways Source Type: research
18 The incidental pulmonary nodule; making sure that no one misses out …
Incidental pulmonary nodules (IPNs) represent a high volume of work with high clinical risk, requiring CT follow up scans so that early lung cancers are not missed. In 2022 we developed a dedicated incidental pulmonary nodule (IPN) service. One of the aims was to gain an understanding of how many IPNs were not referred and or not managed according to the BTS Pulmonary Nodule Guidelines. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Vedas Thakrar, Maria Wolos, Joanna Yates, Adedamola Falolu, Yen Duong, Claire Ridgeon, Rachel Benamore, John Park, Alastair Moore, Ambika Talwar Tags: Clinical Networks and Pathways Source Type: research
19 Utility of blood tests after completion of maintenance durvalumab after radical chemo-radiotherapy in patients with Non Small Cell Lung Cancer stage III
PACIFIC study of adjuvant durvalumab after radical chemoradiotherapy follow-up with 3 monthly blood checks for a year after completion of immunotherapy. We aimed to assess adherence and the added value of this post-treatment routine surveillance in our practice. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Domingo Vicente Cano Gil, Abu Taher, Charlotte Milner-Watts, Alexius John, Faisal Rehman, David McMahon, Michael Davidson, Anna Minchom, Yousaf Nadia, Nadza Tokaca, Sanjay Popat, Jaishree Bhosle, Mary O'Brien Tags: Clinical Networks and Pathways Source Type: research
20 Optimising cancer multi-disciplinary team decision-making in virtual meetings: recommendations from a national mixed-methods study in England
This study aimed to (a) understand how decision-making effectiveness is impacted in VMDTMs, and (b) make recommendations to support best-practice. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Daisy McInnerney, M üntzer Mughal, Donna Chung, Anjola Onifade, David Holden, Martin Birchall, Michael Peake, Samantha Quaife Tags: Clinical Networks and Pathways Source Type: research
21 Barriers to and facilitators of patient engagement in the lung cancer pathway: An interview study exploring the impact of distance and disadvantage in an urban setting
This study aims to explore how patient and carer characteristics, and factors related to their location, interact to influence patients ’ capability, opportunity, and motivation to engage with the NOLCP and improve patient outcomes. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Lucy Mitchinson, Samantha Quaife, David Nelson, Samuel Cooke, Adam Januszewski, Maria Lapuente, Annie Reeves, Ava Harding-Bell, Brian Knowles, Michael D Peake, Zara Pogson, Ros Kane, Ashley Whiteley, Joanne Shuck, Sarah Civello, Dawn Skinner, William Rick Tags: Clinical Networks and Pathways Source Type: research
22 Widening access to ctDNA - lessons from the transformation project in Kent
MTW is spread on two sites and is the main Cancer Centre for the Kent& Medway Cancer Collaborative (KMCC). Approximately, 240 patients are diagnosed annually at MTW. We joined the ctDNA transformation project (TP) in August 2023. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Sandra Wakelin, Eirini Petryoannou, Janice Christie, Katharine Clark, Florina Hewitt, Emma Harrison, Riyaz Shah Tags: Clinical Networks and Pathways Source Type: research
23 Evaluation of pulmonary rehabilitation pilot service in Inverclyde Royal Hospital
Lung cancer causes the greatest cancer mortality in Scotland and is a focus in the Scottish Government's cancer strategy. Prehabilitation optimises patients ’ physical fitness and mental well-being pre-cancer treatment. A prehabilitation service was introduced in December 2022 at Inverclyde Royal Hospital. It offered physiotherapy, dietetic information, smoking cessation, access to financial support, psychological and symptom control. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Zhen Shun Ong, Claribel Patrice Louise Simmons, Pamela Dalrymple Tags: Clinical Networks and Pathways Source Type: research
24 Achieving the 28 day faster diagnosis standard
Following on from the introduction of the 28-day faster diagnosis standard in 2021, University Hospitals Coventry and Warwickshire have implemented several changes to the department to facilitate the achievement of the target. After a fall in demand for the lung cancer services during the COVID pandemic, a significant increase in referrals has been seen. Despite this, the average number of patients seen over a 12-month period within the 28-day target has increased from 47.3% to 75.4% from the years 2022 to 2023. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Judith Vicki Drought, Andrew McDougall Tags: Clinical Networks and Pathways Source Type: research
25 The Gloucestershire Early Lung Cancer Pathway - time for a radical approach?
Patients with early-stage lung cancer (ESLC) suitable for curative treatment, are referred for either surgery or SABR after MDT consideration of the most appropriate treatment. Some patients are subsequently deemed unfit for surgery and then referred for SABR. It was felt the current pathway could lead to treatment delays and multiple appointments can be needed to determine the optimal treatment. To address this the Greater Manchester Cancer Alliance has introduced a lung ‘one-stop cancer clinic’ for joint surgical and oncology review and pre-optimisation. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Rebecca Haggie, Aimee Leadbetter, Henry Steer, Doug West, Samir Guglani, Sean Brown Tags: Clinical Networks and Pathways Source Type: research
26 Implementation of a neoadjuvant lung cancer treatment pathway in a regional tertiary centre
Royal Papworth Hospital (RPH) is a tertiary centre that receives referrals for the management of potentially radically treatable lung cancers from across the East of England. Following results of CheckMate 816 and the subsequent NICE recommendation [TA876], neoadjuvant chemo/immunotherapy was introduced at RPH in April 2023 for patients with a surgically resectable tumour>4 cm or node positive NSCLC. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Laura Succony, Maureen King, Stephen Preston, David Meek, Lavinia McGee, Martin Goddard, Giuseppe Aresu, Robert Rintoul, Nicola Thompson, David Gilligan Tags: Clinical Networks and Pathways Source Type: research
